Technical Analysis for CLLS - Cellectis S.A.

Grade Last Price % Change Price Change
grade C 13.53 -1.17% -0.16
CLLS closed down 1.17 percent on Friday, November 15, 2019, on 79 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical CLLS trend table...

Date Alert Name Type % Chg
Slingshot Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Gilligan's Island Sell Setup Bearish Swing Setup -1.17%
Pocket Pivot Bullish Swing Setup -1.17%
Wide Bands Range Expansion -1.17%
Gapped Up Strength -1.17%
Overbought Stochastic Strength -1.17%
Wide Bands Range Expansion 1.81%

Older signals for CLLS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company's products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.
Medicine Biopharmaceutical Cancer Solid Tumors Acute Myeloid Leukemia Multiple Myeloma Leukemia Chronic Lymphocytic Leukemia Glioblastoma Hematologic Malignancies Solid Tumor Oncogenes Adoptive Cell Transfer Tumors Of The Hematopoietic And Lymphoid Tissues Acute Lymphoblastic Leukemia Cellectis
Is CLLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 22.66
52 Week Low 9.5
Average Volume 112,166
200-Day Moving Average 15.37
50-Day Moving Average 11.4294
20-Day Moving Average 12.1135
10-Day Moving Average 13.083
Average True Range 0.4948
ADX 41.43
+DI 38.6903
-DI 11.9189
Chandelier Exit (Long, 3 ATRs ) 12.4956
Chandelier Exit (Short, 3 ATRs ) 11.3844
Upper Bollinger Band 14.3473
Lower Bollinger Band 9.8797
Percent B (%b) 0.82
BandWidth 36.881166
MACD Line 0.7022
MACD Signal Line 0.5336
MACD Histogram 0.1687
Fundamentals Value
Market Cap 484.23 Million
Num Shares 35.8 Million
EPS -2.30
Price-to-Earnings (P/E) Ratio -5.88
Price-to-Sales 23.25
Price-to-Book 4.09
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.09
Resistance 3 (R3) 14.08 13.89 13.99
Resistance 2 (R2) 13.89 13.75 13.89 13.96
Resistance 1 (R1) 13.71 13.66 13.80 13.72 13.93
Pivot Point 13.52 13.52 13.57 13.52 13.52
Support 1 (S1) 13.34 13.38 13.43 13.35 13.13
Support 2 (S2) 13.15 13.29 13.15 13.10
Support 3 (S3) 12.97 13.15 13.07
Support 4 (S4) 12.98